Navigation Links
FRC Urges FDA to Reject New Abortion Drug Falsely Labeled as an Emergency Contraceptive
Date:6/16/2010

WASHINGTON, June 16 /PRNewswire-USNewswire/ -- Tomorrow, the Food and Drug Administration (FDA) will hold a hearing to consider approval of a new drug application for an abortifacient drug, ulipristal acetate, as an emergency contraceptive, or a new "Plan B."

(Logo: http://photos.prnewswire.com/prnh/20080930/FRCLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO)

Jeanne Monahan, Family Research Council's Director for the Center for Human Dignity, released the following statement urging the FDA to reject the drug application:

"The drug manufacturer's application is very misleading because the chemical makeup of ulipristal is almost identical to mifepristone, popularly known as RU-486, which is primarily an abortifacient. While the drug can act in a way that inhibits ovulation, it also can act as an abortifacient.

"Women deserve to know the truth about drugs that are marketed to them, and the effects the drugs may have on their health and well-being. The FDA must seriously consider the adverse health effects the drug could have on women, in particular infection and severe bleeding as has been seen with RU-486.

"In the words of the American Association of Pro-Life Obstetricians and Gynecologists (AAPLOG), 'Ulipristal acetate is an abortifacient of the same type as mifepristone (RU-486) and... its approval as an emergency contraceptive raises serious health and ethical issues. Furthermore, ulipristal's potential effects on women who used the drug off-label and upon ongoing pregnancies are essentially unexamined and untested.'

"Both ulipristal and mifepristone block the key early pregnancy hormone, progesterone, from functioning properly which effectively starves the embryo. That action potentially can interfere with or end an established pregnancy.

"Women deserve to know what the drug is doing in their body. Preventing human life from beginning is not the same as destroying a life that has already begun. And to many women it is a distinction that makes all the difference.

"We urge the FDA to take seriously its role to protect innocent human life and safeguard the health of American women by rejecting this abortion drug. We also urge a thorough review process to ensure that women's health is not jeopardized just to advance the agenda of the abortion industry."


'/>"/>
SOURCE Family Research Council
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HCD Research Executive Urges Pharmaceutical Industry to Leverage Social Media to Enhance Traditional Marketing Research
2. Mike Burgess Named Head of Oncology Discovery Translational Area for Roches Pharma Research and Early Development (pRED) Organization
3. DEP Urges Medical Facilities to Take Proper Precautions With X-Ray Equipment to Avoid Health Hazards
4. OrthoWorx Urges Warsaws Inclusion on High-Speed Rail Corridor Connecting Chicago and Cleveland
5. Pharmacist Urges Nebraska Medicare Beneficiaries to Compare Prescription Plans
6. Department of Health Urges Expanded H1N1 Vaccination Efforts to Include All Patients
7. RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgans Drug Importation Plan Puts Seniors at Risk
8. CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices
9. DEP Urges Pennsylvanians to Take Precautions to Reduce West Nile Virus Threat
10. McCaughey Urges Use of First NYS Hospital Infection Report
11. Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... , ... TherapySites, the leading website and online ... Counseling Association. This new relationship allows TherapySites to continue to extend their ... benefits and promotional offers. , "TCA is extremely excited about this new partnership, ...
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
Breaking Medicine News(10 mins):